RED BLOOD CELLS iStock-860621344-min.jpg

Targeting Deadly Diseases With Remote-Controlled Ride-Sharing

It’s not science fiction anymore.

Listen to a message from the founder of Global Cancer Technology (GCT), John Clark
John Clark is a seasoned and serial entrepreneur with deep expertise in medical technologies. In this video, he offers insights into some of the technology available to GCT and how their innovative approach drug delivery using remote-control for exceptional precision and timing.

How does Global Cancer Technology do it?

21st century ride-sharing meets remote-control.

 

  1. We attach an inactive cancer drug to our proprietary nanoparticles which are designed to attach to the tumor. 

  2. Once enough nanoparticles accumulate at the tumor’s surface, we use remote-control to apply a small dose of radiation (about 1/400th of a standard chest x-ray). 

  3. Radiation breaks the bonds between the drug and the nanoparticle to activate the drug.

  4. Once activated, the drug and releases the full force of that bond energy directly into the tumor to attack it.

RED BLOOD CELLS iStock-860621344-min.jpg

GCT has numerous patents and other IP that might lead to breakthroughs in cancer therapy. We are partnering with highly acclaimed academic institutions such as UCSD, the Barrow Neurological Institute, Baylor Scott & White Health, Imagion, along with renowned industry leaders to make these therapies available to patients as quickly as possible. 

RED BLOOD CELLS iStock-860621344-min.jpg

Consider making an investment today that may change the future of patients afflicted with cancer, COVID, and other diseases.

*Investments in early-stage biopharmaceutical companies carries risk and returns are not guaranteed. Contact us for Preferred Pricing for investments of $10,000 or more.

Glioblastoma – an Incurable Brain Cancer
Capture.PNG

If you’re one of the 17,000 patients that die each year from this horrific and incurable brain cancer, there is no cause with greater urgency. 

Some cancers, including brain cancer, have been historically underfunded despite the grim prognosis: nearly all patients diagnosed die within 12-18 months. Hence, there are few to no treatment options.

Research shows that 80% of the instances of recurrence, which are inevitable, appear in the tissue surrounding the resection cavity. The blood-brain barrier imposes biological limitations that make it easier for cancerous cells to invade the brain than it is for them to exit the brain and metastasize elsewhere. 

Targeted delivery using nanoparticles to transport highly selective inhibitors across the blood-brain barrier remains the next frontier for treatment. “Glioblastoma requires an arsenal to combat,” said Dr. Fonkem of the Barrow Neurological Institute, “We view the combination of improved targeting with localized delivery as a novel modality worthy of further exploration.” 

GCT has recently acquired two patents for medicinal compounds that are known to cross the blood-brain barrier and to inhibit cancer: PI3K and Vps34.

Need more info before investing?

RED BLOOD CELLS iStock-860621344-min.jpg

GCT’s RegA+ presents investors with an unusual offer.

Following the close of a previous investment round at $1 per share, Global Cancer Technology opened a new investment round at $2 per share. This is your opportunity to own shares in an emerging medical technology company that is developing a patented nanotechnology treatment that looks promising for multiple forms of cancer, including those that are difficult to treat.

*Investments in early-stage biopharmaceutical companies carries risk and returns are not guaranteed. Contact us for Preferred Pricing for investments of $10,000 or more.

 
  • Facebook
  • LinkedIn
  • YouTube

THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET MAY DEVELOP FOLLOWING THIS OFFERING.

 

THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE SECURITIES OR BLUE SKY LAWS. ALTHOUGH AN OFFERING STATEMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), THAT OFFERING STATEMENT DOES NOT INCLUDE THE SAME INFORMATION THAT WOULD BE INCLUDED IN A REGISTRATION STATEMENT UNDER THE SECURITIES ACT. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO SUBSCRIBERS IN CONNECTION WITH THIS OFFERING.

 

SUBSCRIBERS WHO ARE NOT “ACCREDITED INVESTORS” (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE ACT) ARE SUBJECT TO LIMITATIONS ON THE AMOUNT THEY MAY INVEST, AS SET OUT IN SECTION 4. THE COMPANY IS RELYING ON THE REPRESENTATIONS AND WARRANTIES SET FORTH BY EACH SUBSCRIBER IN THIS SUBSCRIPTION AGREEMENT AND THE OTHER INFORMATION PROVIDED BY SUBSCRIBER IN CONNECTION WITH THIS OFFERING TO DETERMINE THE APPLICABILITY TO THIS OFFERING OF EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT.

 

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

 

THE COMPANY MAY NOT BE OFFERING THE SECURITIES IN EVERY STATE. THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE OR JURISDICTION IN WHICH THE SECURITIES ARE NOT BEING OFFERED.

 

THE COMPANY RESERVES THE RIGHT IN ITS SOLE DISCRETION AND FOR ANY REASON WHATSOEVER TO MODIFY, AMEND AND/OR WITHDRAW ALL OR A PORTION OF THE OFFERING AND/OR ACCEPT OR REJECT IN WHOLE OR IN PART ANY PROSPECTIVE INVESTMENT IN THE SECURITIES OR TO ALLOT TO ANY PROSPECTIVE INVESTOR LESS THAN THE AMOUNT OF SECURITIES SUCH INVESTOR DESIRES TO PURCHASE. EXCEPT AS OTHERWISE INDICATED, THE OFFERING MATERIALS SPEAK AS OF THEIR DATE. NEITHER THE DELIVERY NOR THE PURCHASE OF THE SECURITIES SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THAT DATE.

© 2021 by Global Cancer Technology